Cargando…

Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction

INTRODUCTION: Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare neurological hereditary disease clinically characterized as severe, progressive, and life-threatening while the age of onset represents the moment in time when the first symptoms are felt. In this study, we present and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedroto, Maria, Coelho, Teresa, Jorge, Alípio, Mendes-Moreira, João
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393122/
https://www.ncbi.nlm.nih.gov/pubmed/37533468
http://dx.doi.org/10.3389/fneur.2023.1216214
_version_ 1785083097273860096
author Pedroto, Maria
Coelho, Teresa
Jorge, Alípio
Mendes-Moreira, João
author_facet Pedroto, Maria
Coelho, Teresa
Jorge, Alípio
Mendes-Moreira, João
author_sort Pedroto, Maria
collection PubMed
description INTRODUCTION: Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare neurological hereditary disease clinically characterized as severe, progressive, and life-threatening while the age of onset represents the moment in time when the first symptoms are felt. In this study, we present and discuss our results on the study, development, and evaluation of an approach that allows for time-to-event prediction of the age of onset, while focusing on genealogical feature construction. MATERIALS AND METHODS: This research was triggered by the need to answer the medical problem of when will an asymptomatic ATTRv patient show symptoms of the disease. To do so, we defined and studied the impact of 77 features (ranging from demographic and genealogical to familial disease history) we studied and compared a pool of prediction algorithms, namely, linear regression (LR), elastic net (EN), lasso (LA), ridge (RI), support vector machines (SV), decision tree (DT), random forest (RF), and XGboost (XG), both in a classification as well as a regression setting; we assembled a baseline (BL) which corresponds to the current medical knowledge of the disease; we studied the problem of predicting the age of onset of ATTRv patients; we assessed the viability of predicting age of onset on short term horizons, with a classification framing, on localized sets of patients (currently symptomatic and asymptomatic carriers, with and without genealogical information); and we compared the results with an out-of-bag evaluation set and assembled in a different time-frame than the original data in order to account for data leakage. RESULTS: Currently, we observe that our approach outperforms the BL model, which follows a set of clinical heuristics and represents current medical practice. Overall, our results show the supremacy of SV and XG for both the prediction tasks although impacted by data characteristics, namely, the existence of missing values, complex data, and small-sized available inputs. DISCUSSION: With this study, we defined a predictive model approach capable to be well-understood by medical professionals, compared with the current practice, namely, the baseline approach (BL), and successfully showed the improvement achieved to the current medical knowledge.
format Online
Article
Text
id pubmed-10393122
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103931222023-08-02 Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction Pedroto, Maria Coelho, Teresa Jorge, Alípio Mendes-Moreira, João Front Neurol Neurology INTRODUCTION: Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare neurological hereditary disease clinically characterized as severe, progressive, and life-threatening while the age of onset represents the moment in time when the first symptoms are felt. In this study, we present and discuss our results on the study, development, and evaluation of an approach that allows for time-to-event prediction of the age of onset, while focusing on genealogical feature construction. MATERIALS AND METHODS: This research was triggered by the need to answer the medical problem of when will an asymptomatic ATTRv patient show symptoms of the disease. To do so, we defined and studied the impact of 77 features (ranging from demographic and genealogical to familial disease history) we studied and compared a pool of prediction algorithms, namely, linear regression (LR), elastic net (EN), lasso (LA), ridge (RI), support vector machines (SV), decision tree (DT), random forest (RF), and XGboost (XG), both in a classification as well as a regression setting; we assembled a baseline (BL) which corresponds to the current medical knowledge of the disease; we studied the problem of predicting the age of onset of ATTRv patients; we assessed the viability of predicting age of onset on short term horizons, with a classification framing, on localized sets of patients (currently symptomatic and asymptomatic carriers, with and without genealogical information); and we compared the results with an out-of-bag evaluation set and assembled in a different time-frame than the original data in order to account for data leakage. RESULTS: Currently, we observe that our approach outperforms the BL model, which follows a set of clinical heuristics and represents current medical practice. Overall, our results show the supremacy of SV and XG for both the prediction tasks although impacted by data characteristics, namely, the existence of missing values, complex data, and small-sized available inputs. DISCUSSION: With this study, we defined a predictive model approach capable to be well-understood by medical professionals, compared with the current practice, namely, the baseline approach (BL), and successfully showed the improvement achieved to the current medical knowledge. Frontiers Media S.A. 2023-07-17 /pmc/articles/PMC10393122/ /pubmed/37533468 http://dx.doi.org/10.3389/fneur.2023.1216214 Text en Copyright © 2023 Pedroto, Coelho, Jorge and Mendes-Moreira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Pedroto, Maria
Coelho, Teresa
Jorge, Alípio
Mendes-Moreira, João
Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
title Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
title_full Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
title_fullStr Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
title_full_unstemmed Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
title_short Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction
title_sort clinical model for hereditary transthyretin amyloidosis age of onset prediction
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393122/
https://www.ncbi.nlm.nih.gov/pubmed/37533468
http://dx.doi.org/10.3389/fneur.2023.1216214
work_keys_str_mv AT pedrotomaria clinicalmodelforhereditarytransthyretinamyloidosisageofonsetprediction
AT coelhoteresa clinicalmodelforhereditarytransthyretinamyloidosisageofonsetprediction
AT jorgealipio clinicalmodelforhereditarytransthyretinamyloidosisageofonsetprediction
AT mendesmoreirajoao clinicalmodelforhereditarytransthyretinamyloidosisageofonsetprediction